natgillin/translations-raw huggingface dataset:
When injecting regularly, the injection site should be changed between different areas of the body to help reduce potential pain and irritation
Kada se injekcije primjenjuju redovito, injekcije treba davati na različita mjesta na tijelu kako bi se smanjila mogućnost pojave bola i nadraženosti.
When Innovax-ILT is given to chickens, the animals’ immune system recognises the virus as ‘foreign’ and makes antibodies against it.
Kada se cjepivo Innovax-ILT da pilićima, imunosni sustav životinje prepoznaje virus kao „strano tijelo” i proizvodi antitijela protiv njega.
When insulin comes out of the needle tip, your pen is working correctly.
Ako inzulin izlazi kroz vrh igle, brizgalica radi ispravno.
when invasive tests cannot be performed, or when there are discordant results arising from invasive tests.
kada nije moguće primijeniti invazivne dijagnostičke metode, ili kada su nalazi dobiveni invazivnim metodama proturječni.
When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g.
Kad se irbesartan primijeni zajedno s malom dozom hidroklorotiazida (primjerice
When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g.
Kada je ibesartan primijenjen istodobno s niskom dozom hidroklorotiazida (npr.
When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g.
Kada se irbesartan daje istodobno s niskom dozom hidroklorotiazida (npr.
When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g.
Kada se irbesartan primjenjuje istodobno s niskom dozom hidroklorotiazida (npr.
When Irbesartan/Hydrochlorothiazide Teva is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.
Kad Irbesartan/Hidroklorotiazid Teva uzimaju bolesnici s oštećenom funkcijom bubrega, preporučuje se periodički kontrolirati razine kalija, kreatinina i mokraćne kiseline u serumu.
When it attaches to these receptors in the airways, it causes the muscles to relax, which keeps the airways open and helps with the patient’s breathing.
Prilikom spajanja na ove receptore u dišnim putovima, uzrokuje opuštanje mišića, što održava dišne putove otvorenima i pomaže bolesniku pri disanju.
When it attaches to these receptors in the airways, it causes the muscles to relax, which keeps the airways open and helps with the patient’s breathing.
Prilikom spajanja na ove receptore, uzrokuje opuštanje mišića, što održava dišne putove otvorenima i pomaže bolesniku pri disanju.
When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open and helps with the patient’s breathing.
Kad se vežu na te receptore, uzrokuju opuštanje mišića, što održava zračne putove otvorenima i olakšava disanje bolesnika.
When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open and helps with the patient’s breathing.
Prilikom spajanja na ove receptore, uzrokuje opuštanje mišića, što održava zračne putove otvorenima i pomaže pri disanju bolesnika.
When it has been agreed by the CHMP that the S-PSUR is no longer necessary, a full PSUR covering the period since the data lock point of the last routine PSUR will be submitted within a time frame to be agreed with the Rapporteur.
Kada CHMP odluči da S-PSUR-ovi više nisu potrebni, s Izvjestiteljem će se dogovoriti rok u kojem će se napisati potpuni PSUR koji obuhvaća vremensko razdoblje nakon datuma zaključavanja baze od posljednjeg rutinskog PSUR-a.
When it has been agreed by the CHMP that the S-PSUR is no longer necessary, a full PSUR covering the period since the data lock point of the last routine PSUR will be submitted within a time frame to be agreed with the Rapporteur.
Kada s CHMP-om bude dogovoreno da S-PSUR izvješća više nisu potrebna, unutar vremenskog roka dogovorenog s izvjestiteljem, podnijet će se cjelovito PSUR izvješće za razdoblje od datuma zaključavanja baze podataka zadnjeg redovitog PSUR izvješća.
When it is appropriate to titrate down to a lower strength not available for Aerivio Spiromax, a change to an alternative fixed-dose combination of salmeterol and fluticasone propionate containing a lower dose of the inhaled corticosteroid is required.
Kada je dozu primjereno titrirati na manju od one dostupne u ovom lijeku, Aerivio Spiromax je potrebno zamijeniti drugom fiksnom kombinacijom salmeterola i flutikazonpropionata koja sadrži nižu dozu inhalacijskog kortikosteroida.
When it is appropriate to titrate down to a lower strength not available for Aerivio Spiromax, a change to an alternative fixed-dose combination of salmeterol and fluticasone propionate containing a lower dose of the inhaled corticosteroid is required.
Kada je dozu primjereno titrirati na manju od one dostupne u ovom lijeku, Airexar Spiromax je potrebno zamijeniti drugom fiksnom kombinacijom salmeterola i flutikazonpropionata koja sadrži nižu dozu inhalacijskog kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for BiResp Spiromax, a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kad je primjereno titriranje doze na nižu jačinu od one koja je dostupna u inhalatoru BiResp Spiromax, potrebna je promjena na drugi kombinirani lijek s fiksnom dozom budezonida i formoterol fumarata, koji sadrži nižu dozu inhalacijskog kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for BiResp Spiromax, a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kad je primjereno titrirati dozu na nižu jačinu od one koja je dostupna u lijeku DouResp Spiromax, potrebna je zamjena s drugim kombiniranim lijekom s fiksnom dozom budezonida i formoterolfumarata, koji sadrži nižu dozu inhalacijskog kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for BiResp Spiromax, a change to an alternative fixed–dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kad je primjereno titriranje doze na nižu jačinu od one koja je dostupna u inhalatoru BiResp Spiromax, potrebna je promjena na drugi kombinirani lijek s fiksnom dozom budezonida i formoterol fumarata, koji sadrži nižu dozu inhalacijskog kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for Budesonide/Formoterol Teva , a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kad je primjereno titrirati dozu na nižu jačinu od one koja je dostupna u lijeku Budezonid/Formoterol Teva, potrebna je zamjena s drugim kombiniranim lijekom s fiksnom dozom budezonida i formoterolfumarata, koji sadrži nižu dozu inhalacijskog kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for Budesonide/Formoterol Teva Pharma B.V., a change to an alternative fixed–dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kad je primjereno titriranje doze na nižu jačinu od one koja je dostupna u inhalatoru Budezonid/Formoterol Teva Pharma B.V., potrebna je promjena na drugi kombinirani lijek s fiksnom dozom budezonida i formoterol fumarata, koji sadrži nižu dozu inhalacijskog kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for Budesonide/Formoterol Teva, a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kad je primjereno titrirati dozu na nižu jačinu od one koja je dostupna u lijeku Budezonid/Formoterol Teva, potrebna je zamjena s drugim kombiniranim lijekom s fiksnom dozom budezonida i formoterolfumarata, koji sadrži nižu dozu inhalacijskog kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for Budesonide/Formoterol Teva, a change to an alternative fixed–dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kad je primjereno titriranje doze na nižu jačinu od one koja je dostupna u inhalatoru Budezonid/Formoterol Teva, potrebna je promjena na drugi kombinirani lijek s fiksnom dozom budezonida i formoterol fumarata, koji sadrži nižu dozu inhalacijskog kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for DuoResp Spiromax, a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kad je primjereno titriranje doze na nižu jačinu od one koja je dostupna u inhalatoru DuoResp Spiromax, potrebna je promjena na drugi kombinirani lijek s fiksnom dozom budezonida i formoterol fumarata, koji sadrži nižu dozu inhalacijskog kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for DuoResp Spiromax, a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kad je primjereno titrirati dozu na nižu jačinu od one koja je dostupna u lijeku DuoResp Spiromax, potrebna je zamjena s drugim kombiniranim lijekom s fiksnom dozom budezonida i formoterolfumarata, koji sadrži nižu dozu inhalacijskog kortikosteroida.
When it is appropriate to titrate down to a lower strength than is available for DuoResp Spiromax, a change to an alternative fixed–dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Kad je primjereno titriranje doze na nižu jačinu od one koja je dostupna u inhalatoru DuoResp Spiromax, potrebna je promjena na drugi kombinirani lijek s fiksnom dozom budezonida i formoterol fumarata, koji sadrži nižu dozu inhalacijskog kortikosteroida.
When it is blocked, a substance called ‘cyclic guanine monophosphate’ (cGMP) cannot be broken down, so that it remains in the vessels where it causes relaxation and widening of the blood vessels.
Kada se enzim inhibira, tvar „ciklički gvanozin monofosfat” (cGMP) ne može se razgraditi te zbog toga ostaje u krvnim žilama i uzrokuje njihovo opuštanje i širenje.
When it is given during an angioedema attack, conestat alfa stops this excessive activity, helping to relieve the patient’s symptoms.
Ako se primjenjuje tijekom napadaja angioedema, konestat alfa zaustavlja tu prekomjernu aktivnost, pomažući tako pri ublažavanju simptoma u bolesnika.
When it is given to cattle or sheep, the animals’ immune system recognises the virus as foreign and makes antibodies against it.
Kada se cjepivo daje govedima ili ovcama, imunosni sustav životinje prepoznaje virus kao „strano tijelo“ i proizvodi antitijela protiv njega.
When it is given to piglets (or their mothers), the immune system recognises the virus as ‘foreign’ and makes antibodies against it.
Kada se cjepivo daje prasadi (ili njihovim majkama), imunosni sustav prepoznaje virus kao „strano tijelo“ i proizvodi antitijela protiv njega.
When it is given to sheep and cattle, the animals’ immune systems recognise the viruses as ‘foreign’ and make antibodies against them.
Kada se cjepivo daje ovcama ili govedima, imunosni sustav životinje prepoznaje virus kao „strano tijelo” i proizvodi protutijela za njega.
When it is time for your next routine dose, go to Section 3, Step 1, and repeat Steps 1 - 7.
Kada dođe vrijeme za Vašu sljedeću redovnu dozu, idite na Dio 3, Korak 1, i ponovite Korake 1 - 7.
When it was added to paclitaxel, the average progression-free survival was 11.4 months, compared with 5.8 months in those receiving paclitaxel alone.
Ako se dodao paklitakselu, prosječno razdoblje preživljenja bez progresije iznosilo je 11,4 mjeseca, u usporedbi s 5,8 mjeseci u osoba koje su primale samo paklitaksel.
When it was compared with dolasetron, these values were 63% for Aloxi (119 patients out of 189) and 53% for dolasetron (101 patients out of 191).
U slučaju usporedbe s dolasetronom, ove vrijednosti su iznosile 63% za Aloxi (119 bolesnika od 189) i 53% za dolasetron (101 bolesnik od 191).
When it was used in combination with ribavirin in adults, Pegasys was more effective than when it was used on its own (45% responders at follow-up compared with 24%), and was as effective as the combination of interferon alfa-2a and ribavirin (39% responders).
Kad se koristio u kombinaciji s ribavirinom u odraslih, Pegasys je bio djelotvorniji nego kad se koristio samostalno (45 % bolesnika koji su reagirali na liječenje prilikom kontrole u usporedbi s njih 24 %) i bio je jednako djelotvoran kao i kombinacija interferona alfa-2a i ribavirina (39 % bolesnika koji su reagirali na liječenje).
When Jakavi is administered with strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole) the unit dose of Jakavi should be reduced by approximately 50%, to be administered twice daily (see section 4.5).
Kada se Jakavi primjenjuje sa snažnim CYP3A4 inhibitorima ili dvostrukim inhibitorima enzima CYP2C9 i CYP3A4 (npr. flukonazolom), jediničnu dozu Jakavija treba smanjiti za otprilike 50% te je primjenjivati dvaput na dan (vidjeti dio 4.5).
When judged necessary, the doctor may monitor the level of caffeine in the baby’s blood and adjust the dose accordingly.
Ako se ocjeni potrebnim, liječnik može pratiti koncentracije kofeina u krvi bebe i prilagoditi dozu prema tome.
When ketoconazole was co-administered with trabectedin, the plasma exposure of trabectedin was increased by approximately 21% for Cmax and 66% for AUC, but no new safety concerns were identified.
Kod istodobne primjene ketonazola sa trabektedinom, izloženost trabektedinu u plazmi bila je povećana za 21% za Cmax i 66% za AUC, ali bez identificiranih novih sigurnosnih pitanja.
When laboratory abnormalities and adverse events were combined across concomitant and monotherapy treatment phases, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic events were observed in 8 % of the patients.
Kad su se objedinila odstupanja laboratorijskih nalaza i nuspojave iz faze istodobnog liječenja i faze monoterapije, poremećaji broja neutrofila stupnja 3 ili 4, uključujući neutropeniju, zabilježeni su u 8% bolesnika.
When lamivudine therapy was continued post transplantation there was reduced graft re-infection by HBV, increased HBsAg loss and on one-year survival rate of 76 – 100 %.
Kad se liječenje lamivudinom nastavilo i nakon transplantacije došlo je do smanjenja reinfekcije transplantata HBV-om, povećanog gubitka HBsAg, a stopa jednogodišnjeg preživljavanja iznosila je 76-100 %.
When lamivudine therapy was continued post transplantation there was reduced graft re-infection by HBV, increased HBsAg loss and on one-year survival rate of 76-100 %.
Kad se liječenje lamivudinom nastavilo i nakon transplantacije, došlo je do smanjenja reinfekcije transplantata HBV-om, povećanog gubitka HBsAg, a stopa jednogodišnjeg preživljavanja iznosila je 76-100 %.
When lamivudine was discontinued, the majority of patients (70 %) had a return of viral replication.
Nakon prekida liječenja lamivudinom, u većine bolesnika (70%) je ponovo nastupila replikacija virusa.
When ledipasvir/sofosbuvir was studied with ribavirin, the most frequent adverse drug reactions to ledipasvir/sofosbuvir + ribavirin combination therapy were consistent with the known safety profile of ribavirin, without increasing the frequency or severity of the expected adverse drug reactions.
Kad se ledipasvir/sofosbuvir ispitivao s ribavirinom, najčešće nuspojave kombinirane terapije ledipasvira/sofosbuvira + ribavirin bile su sukladne poznatom sigurnosnom profilu kod liječenja ribavirinom, bez povećanja učestalosti ili težine očekivanih nuspojava.
When less levodopa is required, the total daily dose of Levodopa/Carbidopa/Entacapone Orion should be reduced either by decreasing the frequency of administration by extending the time between doses, or by decreasing the strength of Levodopa/Carbidopa/Entacapone Orion at an administration.
Kada je potrebno manje levodope, ukupna dnevna doza Levodopa/Carbidopa/Entacapone Oriona mora se smanjiti ili smanjenjem učestalosti primjene povećanjem vremenskog razmaka između doza ili primjenom manje jačine Levodopa/Carbidopa/Entacapone Oriona.
When Letifend is given to dogs the immune system recognises the Leishmania protein as ‘foreign’ and makes defences against it.
Kada se Letifend daje psima, imunosni sustav prepoznaje bjelančevinu parazita Leishmania kao „strano tijelo” i stvara obrambeni mehanizam protiv nje.
When Levemir is used as part of a basal-bolus insulin regimen Levemir should be administered once or twice daily depending on patients’ needs.
Kad se Levemir primjenjuje u sklopu bazal-bolus inzulinske terapije, Levemir treba primijeniti jednom ili dva puta dnevno, ovisno o bolesnikovim potrebama.
When Levemir is used as part of a basal-bolus insulin regimen, Levemir should be administered once or twice daily depending on patients’ needs.
Kad se Levemir primjenjuje u sklopu bazal-bolus inzulinske terapije, Levemir treba primijeniti jednom ili dva puta dnevno, ovisno o bolesnikovim potrebama.
When linagliptin and metformin were administered in combination with a sulphonylurea, hypoglycaemia was the most frequently reported adverse event (linagliptin plus metformin plus sulphonylurea 23.9% and 16.0% in placebo plus metformin plus sulphonylurea).
Kada su se linagliptin i metformin primijenili u kombinaciji sa sulfonilurejom, hipoglikemija je bila najčešće prijavljeni štetni događaj (linagliptin plus metformin plus sulfonilureja 23,9% i 16,0% u kombinaciji placebo plus metformin plus sulfonilureja).
When linagliptin and metformin were administered in combination with insulin, constipation was identified as an additional adverse reaction under these conditions.
Kada su linagliptin i metformin bili primjenjivani u kombinaciji s inzulinom, kao dodatna nuspojava u navedenim uvjetima prepoznata je konstipacija.
When linagliptin and metformin were administered in combination with insulin, hypoglycaemia was the most frequently reported adverse event, but occurred at comparable rate when placebo and metformin were combined with insulin (linagliptin plus metformin plus insulin 29.5% and 30.9% in the placebo plus metformin plus insulin group) with a low rate of severe episodes (1.5% and 0.9%).
Kada su linagliptin i metformin bili primjenjivani u kombinaciji s inzulinom, hipoglikemija je bila najčešće prijavljeni štetni događaj, ali sa stopom pojavnosti usporedivom kombiniranoj primjeni placeba i metformina s inzulinom (skupina na kombinaciji linagliptin plus metformin plus inzulin 29,5% i 30,9% u skupini na kombinaciji placebo plus metformin plus inzulin) s niskom stopom teških epizoda (1,5% i 0,9%).
When lomitapide 20 mg was co-administered simultaneously or 12 hours apart with ethinyl estradiol/norgestimate, a weak CYP3A4 inhibitor, no clinically meaningful increase in lomitapide exposure was observed.
Kad se lomitapid 20 mg primjenjivao istovremeno ili u razmaku od 12 sati s etinilestradiolom/norgestimatom, slabim inhibitorom CYP3A4, nije bilo opaženo klinički značajno povećanje u izloženosti lomitapidu.
When lomitapide 20 mg was co-administered simultaneously with atorvastatin, a weak CYP3A4 inhibitor, lomitapide AUC and Cmax increased approximately 2-fold.
Kad se lomitapid 20 mg primjenjivao istodobno s atorvastatinom, slabim inhibitorom CYP3A4, AUC i Cmax lomitapida povećali su se približno dvaput.
When lomitapide 60 mg was administered to steady state prior to atorvastatin 20 mg, atorvastatin acid AUC and Cmax increased 52% and 63%, respectively.
Primijena lomitapida 60 mg u stanju dinamičke ravnoteže prije atorvastatina 20 mg, uzrokovala je povećanje AUC i Cmax atorvastatinske kiseline za 52% odnosno 63%.
When lomitapide 60 mg was administered to steady state prior to rosuvastatin 20 mg, rosuvastatin Tmax increased from 1 to 4 hours, AUC was increased 32%, and its Cmax was unchanged.
Primijena lomitapida 60 mg u stanju dinamičke ravnoteže prije rosuvastatina 20 mg, vrijednost Tmax rosuvastatina povećala se s 1 na 4 sata, AUC se povećao 32%, a Cmax bio je nepromijenjen.
When Lonsurf at a single dose of 35 mg/m2 was administered to 14 patients with solid tumours after a standardised high-fat, high-calorie meal, trifluridine area under the concentration-time curve (AUC) did not change, but trifluridine Cmax, tipiracil hydrochloride Cmax and AUC decreased by approximately 40% compared to those in a fasting state.
Kada je primijenjena jedna doza Lonsurfa od 35 mg/m2/dozi u 14 bolesnika sa solidnim tumorima nakon standardiziranog punomasnog, visokokaloričnog obroka, površina ispod krivulje koncentracija- vrijeme (AUC) za trifluridin se nije promijenila, ali su Cmax trifluridina i Cmax tipiracilklorida kao i AUC smanjene za oko 40% u usporedbi s vrijednostima na tašte.
When looking at certain abnormalities in the brain, Optimark may need to be used at three times the usual dose in one injection in adults.
Kada se traže određene abnormalnosti u mozgu, kod odraslih će možda biti potrebno primijeniti jednu injekciju s trostruko većom dozom Optimarka od uobičajene.
When looking at certain abnormalities in the brain, Optimark may need to be used at three times the usual dose in one injection in adults.
Kada se traže određene promjene u mozgu, kod odraslih će možda biti potrebno primijeniti jednu injekciju s trostruko većom dozom Optimarka od uobičajene.
When looking at the results of both main studies together, 48% (115 out of 241) of adults who previously had an inadequate response to laxatives and who took 25 mg Moventig responded to treatment compared with 30% (72 out of 239) of adults on placebo.
48 % (115 od 241) odraslih bolesnika koji su prethodno neodgovarajuće reagirali na laksative i koji su uzimali 25 mg lijeka Moventig reagiralo je na liječenje u usporedbi s 30 % (72 od 239) odraslih bolesnikakoji su uzimali placebo.
When lurasidone is coadministered with mild or moderate CYP3A4 inducers, the efficacy of lurasidone needs to be carefully monitored and a dose adjustment may be needed.
Kad se lurasidon primjenjuje s blagim ili umjerenim CYP3A4 induktorima, potrebno je pomno nadzirati djelotvornost lurasidona i može biti potrebnoprilagoditi dozu.
When Lynparza is bound to the active site of DNA-associated PARP it prevents the dissociation of PARP and traps it on the DNA, thus blocking repair.
Nakon što se Lynparza veže za aktivno mjesto PARP-a spojenog za DNK, on sprječava odvajanje PARP-a i drži ga pričvršćenim za DNK te tako onemogućuje popravak.
When Lyrica is taken with other medicines that may cause constipation (such as some types of pain medicines) it is possible that gastrointestinal problems may occur (e.g. constipation, blocked or paralysed bowel).
Kada se Lyrica uzima s drugim lijekovima koji mogu uzrokovati zatvor (kao što su neke vrste lijekova protiv bolova), moguće je da se pojave probavne tegobe (primjerice zatvor, blokada ili paraliza crijeva).
When MabThera is given in combination with chemotherapy, standard dose reductions for the chemotherapeutic medicinal products should be applied (see section 4.8).
Kad se MabThera primjenjuje u kombinaciji s kemoterapijom, moraju se primijeniti uobičajena smanjenja doze kemoterapijskih lijekova (vidjeti dio 4.8).
When made up into a solution, SonoVue contains sulphur hexafluoride gas as ‘microbubbles’ in suspension in a liquid.
Kada se pomiješa u otopinu, SonoVue sadrži plin sumporovog heksafluorida kao „mikromjehuriće” u suspenziji u tekućini.
when making the dose
u pojedinog bolesnika (vidjeti
When measurable ( 0.01 ng/ml, the assay limit of quantitation), concentrations ranged from
Kad je bila mjerljiva (≥0,01ng/ml, granica testa mjerenja), koncentracija je bila u rasponu od 0,01 do 0,03 ng/ml.
When medicines are made from human blood or plasma, certain measures are put in place by the manufacturer to prevent infections being passed on to patients.
Prilikom dobivanja lijekova iz ljudske krvi ili plazme proizvođač poduzima određene mjere kako bi spriječio prijenos infekcije na bolesnike.